 Rwy'n gweithio'n gweithio y ffun fath o'r ffordd ar y dylai'r $1 pennyllu. Dyna'n ffordd a hynny'n gweithio'r ddod o'r ffordd fel y ddod. Rwy'n gweithio'n gweithio'n ffynansial gwyrdd. Rwy'n gweithio'n busnes ysgol yn yw'r gweithio'r gweithio, ond rwy'n gweithio'r ddod o'r ddod o'r ffordd. Rwy'n gweithio'r ffynans, oherwydd o'r gweithio'r ddod, That would be fantastic. It helps you to get into that YouTube search results. We're trying to grow to 10,000 subscribers as fast as we can. We cover many penny stocks, we do penny stocks alerts, many of the stocks that we've mentioned have gone up. They've done quite well. We'll go into this information today and we'll get right into it. Who are they? First of all, who are they fund that is buying this penny stock? The fund that's buying this penny stock is BlackRock, a they are a global investment manager serving the UK market for more than 20 years, they committed to helping more people plan for their financial future, no matter your goals, what your goals may be at BlackRock, we have invested in you and these have actually invested in a penny stock and we'll go through what that penny stock is here. So you'll notice here for this penny stock they've actually increased their shares here in this penny stock for 3.7 million, this particular stock that we're going to talk about today and they're continuing to actually build their shares in this so they've got current shares of 3.7 million, they're continuing to buy more here so they must think that this stock's got some sort of prominence or it's really good or there's something good about it and there is a lot of prominent factors about this stock and we'll go through what they are in this particular video. The stock we're talking about today is called Paletin Technologies, the ticker symbol is PTN and you'll notice here that it's actually sat at 0.96 and the forecasts, the analysts actually have this at a low of $2, a medium of $2 and a higher $3 which even the analysts are significantly higher than what its current price is and projected in 12 months is lower to and a higher of $3. So it's saying that it could represent an increase of 107% and it could go even further than the $3 if they're getting these big investment funds and big investment firms investing into PTN if they're getting all these firms this shows promise they've done their research these big investment firms on this stock and they see that there's a potential in this stock hence why they've invested in it and they see that it's growing so it could be the case that we will start to eventually get some analyst upgrades possibly which would then obviously have an impact on the stock price as well and it is going up you know gradually over time here and I think that it's got a lot of potential to really move up to that $2 level very very quickly okay so we'll go into the information about this stock and who they are so who are they who are Palatin so Palatin Technologies is a biopharmaceutical company that's developing targeted receptor specific peptide therapeutics for the treatment of diseases with significant unmedical need and commercial purposes okay and you can see in terms of here what they're involved in so it's a biopharmaceutical company and we have to suggest it some in the past that have done quite well okay so we'll have a look at this one here so going into it what have they got so the company profile they've got technology and expertise in developing drugs that modulate this particular area here then you've got demonstrated expertise moving programs for discovery to FDA approval here and as they become more FDA approved with any of their product pipeline that's just catalyst in itself but but they've also bring in and commercializing products as well which is really important and you know you don't just want to necessarily rely on a product waiting for FDA approval there's got to be more to it because that's a bit risky right because it otherwise it's a stock that's either going to flop or it's going to do really well because it's all determined on one factor you want to get into a penny stock which is determined on a multiple factors right which is which is kind of what this is and then you've got deep expertise in the biology and chemistry of the melakartin system it's got its first company to procedure FDA approval for this strategy leverages our chemistry and biology across multiple therapeutic opportunities we'll go into this particular point in a moment actually there's some updates mrs with the potential to modify underlying disease patho patho pathologist not just treat symptoms brilliant so that is groundbreaking that last point okay so going into this they've also got some licensing agreements some licensing agreements for what they what they've got there they've got a chinese pharmaceutical company focused on developing and commercializing innovative healthcare solutions with two billion in annual sales so they've got some licensing with this company they've got some licensing here and what that means is it's having an impact on the revenue you know the make this is just another revenue source through licensing agreements okay and you can see the financial snapshot here now the really key point that i wanted to make mention here is that they do have cash on hand from june 30 2020 of 82.6 million so they've got a lot of cash on hand which is really important for a for a biopharmaceutical stock why because biopharmaceutical stocks tend to get through a lot of cash because of their research and development so they have a lot of cash band so the fact that there's you know 82.7 to 82.6 million is is good okay and some of the recent updates here he says palatine technologies announces positive results from its phase two study of pl 9643 in patients with dry eye disease and also announced its reports on the first quarter fiscal year of 2021 results and provides a business update in terms of retaining the rights here in terms of receiving 12 million plus 4.3 million here so some revenue it's got phase two clinical results here which was related to that and then also in terms of 86.6 million in cash now as well so they've got a lot of cash at hand which is really important for the business to grow and bit and develop right now the current price of this stock is sat at 0.96 it's on a little bit of a dip after after a bit of a run-up and it's starting to dip a little bit what I would say is if you can get this stock you can get this stock anywhere between 0.70 and 0.90 I would say it's a buying opportunity and I would hold this medium to long I think you've also got to keep keep updated with this stock right because you very much based upon how well their you know their drugs and their solutions do right so you got to keep updated with this stock but I do think it can run up to past those analyst expectations I think you could get to three dollars four dollars five dollars in the longer term and maybe in the medium to short term it could do a double up okay but I do think it's got a lot of potential why because it's got a big total addressable market in terms of some of the drugs that they're producing it's got a great history and what it's doing it's got institutional investors and investment firms very interested in this stock so there's a lot of benefits to this stock here which which is indicating to me that it is seems like a good quality investment that could run up okay so that's my thoughts on that one if you're new to the channel and you want the latest penny stock alerts the latest information on any penny stocks then do subscribe we cover a range of penny stock informations and many of our stocks that we've talked about have run up in uver has run up we were one of the first people to cover tranzentrics that ran up okay so a lot of the stocks we've talked about have ran up and also in addition to that if you're a current subscriber hit the notification bell why because then you get notified as soon as possible when a new video comes out and particularly when a penny stock is time sensitive in terms of getting in your entry to a stock it's really important to get that video straight away right and it comes up on your notifications so thanks everybody for all the support let's hit the road to 10 000 subscribers we're on that road now it's fantastic and I'll see everybody in the next video